This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fracasso, P. M. Articles by Garrett, C. R. Search for Related Content PubMed PubMed Citation Articles by Fracasso, P. M. Articles by Garrett, C. R.

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

Authors' Affiliations: ¹ The Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri; ² Tennessee Oncology, The Sarah Cannon Cancer Center, Nashville, Tennessee; ³ H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; ⁴ Tripath Imaging, Inc., Raleigh, North Carolina; and ⁵ Bristol-Myers Squibb Pharmaceuticals Research Institute, Princeton, New Jersey

Requests for reprints: Christopher R. Garrett, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612-9497. Phone: 813-745-8329; Fax: 813-745-7229; E-mail: garrett{at}moffitt.usf.edu.

Purpose: This phase 1 study evaluated the pharmacokinetic and pharmacodynamic effects of cetuximab on patients with epithelial malignancies.

Experimental Design: Following a skin and tumor biopsy, patients with advanced epithelial malignancies were randomized to receive a single dose of cetuximab at 50, 100, 250, 400, or 500 mg/m² i.v. Repeat skin (days 2, 8, 15, and 22) and tumor (day 8) biopsies were obtained. Immunohistochemical expression of epidermal growth factor receptor (EGFR) and its pathway members was done on biopsies. Blood samples were obtained over 22 days for pharmacokinetic analyses. After day 22, all patients received weekly 250 mg/m² cetuximab until disease progression or unacceptable toxicity.

Results: Thirty-nine patients enrolled. Rash was noted in 26 (67%) patients. Three patients (two with colon cancer and one with laryngeal cancer) achieved a partial response and 13 patients had stable disease. Pharmacokinetic data revealed mean maximum observed cetuximab concentrations and mean area under the concentration-time curve from time zero to infinity increased in a dose-dependent manner up to 400 mg/m² cetuximab. Mean clearance was similar at cetuximab doses 100 mg/m², supporting saturation of EGFR binding at 250 mg/m². Pharmacodynamic evaluation revealed that patients with partial response/stable disease had a higher-grade rash and higher cetuximab trough levels than those with progressive disease (P = 0.032 and 0.002, respectively). Administration of single doses (250-500 mg/m²) of cetuximab resulted in a dose-dependent decrease in EGFR protein expression levels in skin over time, supporting a minimal dose of cetuximab at 250 mg/m² for a pharmacodynamic effect.

Conclusion: This study provides a pharmacokinetic and pharmacodynamic rationale for the dosing of cetuximab.

This article has been cited by other articles:

				D. Tripathy Are We Hitting the Right Combination for Hormonally Sensitive Breast Cancer? J. Clin. Oncol., June 1, 2009; 27(16): 2580 - 2582. [Full Text] [PDF]

				A. J. Mutsaers, G. Francia, S. Man, C. R. Lee, J. M.L. Ebos, Y. Wu, L. Witte, S. Berry, M. Moore, and R. S. Kerbel Dose-Dependent Increases in Circulating TGF-{alpha} and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent Clin. Cancer Res., April 1, 2009; 15(7): 2397 - 2405. [Abstract] [Full Text] [PDF]

				M. Michaelis, J. Bliss, S. C. Arnold, N. Hinsch, F. Rothweiler, H. E. Deubzer, O. Witt, K. Langer, H. W. Doerr, W. S. Wels, et al. Cisplatin-Resistant Neuroblastoma Cells Express Enhanced Levels of Epidermal Growth Factor Receptor (EGFR) and Are Sensitive to Treatment with EGFR-Specific Toxins Clin. Cancer Res., October 15, 2008; 14(20): 6531 - 6537. [Abstract] [Full Text] [PDF]

				J. Thariat, N. Azzopardi, F. Peyrade, V. Launay-Vacher, J. Santini, T. Lecomte, M.-C. Etienne-Grimaldi, G. Paintaud, and G. Milano Cetuximab Pharmacokinetics in End-Stage Kidney Disease Under Hemodialysis J. Clin. Oncol., September 1, 2008; 26(25): 4223 - 4225. [Full Text] [PDF]

				N. L. Dirks, A. Nolting, A. Kovar, and B. Meibohm Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck J. Clin. Pharmacol., March 1, 2008; 48(3): 267 - 278. [Abstract] [Full Text] [PDF]

				J. A. Bonner, K. Ang, W. Budach, E. Bolke, and B. Homey More on Severe Cutaneous Reaction with Radiotherapy and Cetuximab N. Engl. J. Med., November 1, 2007; 357(18): 1872 - 1873. [Full Text] [PDF]